ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177

ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177

ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Radiopharm Theranostics (ASX:RAD; NASDAQ: RADX "Radiopharm"), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, today announced the signing of a supply agreement that will provide Radiopharm with ITM's medical radioisotope, non-carrier-added Lutetium-177 (n.c.a. 177 Lu), to enable its usage in the clinical and potential future commercial development of the 177 Lu-based molecules in Radiopharm's development pipeline.

Under the terms of the agreement, Radiopharm will use ITM's n.c.a. 177 Lu across its clinical pipeline, including in key programs such as RAD 204 (PD-L1-targeting nanobody, Phase 1), RAD 202 (HER2-targeting nanobody, Phase 1), and RV01 (B7-H3-targeting monoclonal antibody, preclinical), for the treatment of solid tumors. Coupled with the targeting molecules that are designed to deliver ITM's n.c.a. 177 Lu directly to tumor sites, the radioisotope emits therapeutic beta radiation with the aim to destroy malignant cells in a highly precise and localized manner.

" Ensuring supply of key isotopes continues to be a priority for our team, allowing us to accelerate our clinical programs ," said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics . " Lutetium-177 is required for three of our more advanced assets and this supply agreement with a radiopharmaceutical leader like ITM is another important step to ensure quality, reliability, and redundancy in our clinical development plans ."

ITM's n.c.a. 177 Lu is a market-approved, highly pure form of the beta-emitting radioisotope, Lutetium-177, that can be linked to tumor-specific targeting molecules for the treatment of various cancers and has been successfully used in numerous clinical and commercial radiopharmaceutical cancer treatments. ITM holds a U.S. Drug Master File (DMF) with the Food and Drug Administration (FDA) for n.c.a. 177 Lu and has marketing authorization in the EU (brand name EndolucinBeta ® ).

" As the leading global manufacturer of non-carrier-added Lutetium-177, we are just as committed to supplying our global partners with high-quality medical radioisotopes as we are to supplying our own pipeline ," said Andrew Cavey, CEO of ITM . " Supporting Radiopharm in the advancement of their therapeutic candidates reflects our shared dedication to delivering improved treatment options to people living with cancer ."

About ITM Isotope Technologies Munich SE
ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple phase 3 studies, combining the company's high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. www.itm-radiopharma.com

About Radiopharm Theranostics
Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain. Learn more at radiopharmtheranostics.com .

Authorised on behalf of the Radiopharm Theranostics board of directors by Chairman Paul Hopper.

For more information:
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

Paul Hopper
Executive Chairman
P: +61 406 671 515
E: paulhopper@lifescienceportfolio.com

Media
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

ITM Contact
Corporate Communications
Kathleen Noonan/Julia Westermeir
Phone: +49 89 329 8986 1500
Email: communications@itm-radiopharma.com

Investor Relations
Ben Orzelek
Phone: +49 89 329 8986 1009
Email: investors@itm-radiopharma.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

RAD:AU
Radiopharm Theranostics

Radiopharm Theranostics Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Radiopharm Theranostics

Radiopharm Theranostics


Keep reading...Show less

Developing innovative radiopharmaceuticals for a highly underserved oncology sector

Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹?¹Tb-KLK3-mAb Phase I Clinical Trial in Australia

Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹?¹Tb-KLK3-mAb Phase I Clinical Trial in Australia

RAD 402 preclinical data package complete; demonstrates safety and promising biodistribution profile

Ethics approval and Phase 1 clinical trial start in prostate cancer anticipated in 2H 2025

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases

Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases

Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for RAD101 to distinguish between recurrent disease and treatment effect of brain metastases originating from solid tumors of different origin including leptomeningeal disease.

RAD101 is the Company's novel imaging small molecule that targets fatty acid synthase (FASN), a multi-enzyme protein that catalyses fatty acid synthesis and is overexpressed in many solid tumors, including cerebral metastases.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Radiopharm Theranostics Doses First Patient in Phase 1 'HEAT' Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors

Radiopharm Theranostics Doses First Patient in Phase 1 'HEAT' Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors

Phase 1 1 First-In-Human study designed to assess safety   ,   tolerability   , right dose for Phase 2 and early signs of efficacy   of 177Lu-RAD20   2   in individuals with   advanced HER2-positive solid   tumors

Previous clinical proof-of concept data 2 for targeting HER-2 demonstrated the safety and biodistribution of 99mTc-RAD202 in humans

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Group of male and female scientists working in laboratory.

Inside the ASX Biotech Boom: What’s Fuelling the Next Wave

Australia’s healthcare and biotechnology sector has matured into one of the most promising and strategically important segments of the ASX. Fortunes can shift on a single clinical trial result. A company with no revenue today could be a global contender tomorrow — if its science holds up.

As investors sift through early stage biotech companies, the challenge is less about spotting ambition and more about recognising the markers of real-world impact: a strong intellectual property (IP) moat, well-timed milestones, non-toxic innovation and enough capital to get through the next inflection point. In a market where data can drive value faster than sales, understanding the rhythm of biotech development has become not just useful, but essential.

According to Australian market analyst firm Morgans, healthcare stocks have consistently delivered strong performances on the ASX over the last 10 years. With more than $8 billion in annual revenue, the Australian life science ecosystem is expected to continue to grow at an annual rate of 3 percent up to 2026.

Keep reading...Show less
Lab worker putting samples on microscope.

Top 4 Small-cap ASX Biotech Stocks of 2025

The global biotechnology sector is on track to become a multi-trillion dollar industry.

Worldwide, the biotech space was worth an estimated US$1.68 trillion last year, according to Cervicorn Consulting. That value is expected to grow at a compound annual growth rate of 9.18 percent through 2033 to become a US$3.54 trillion market.

The major factors driving this growth are a strong clinical pipeline of precision medicine and regenerative technologies, as well as a rising demand for treatments for chronic diseases such as cancer, diabetes and neurological disorders.

Keep reading...Show less
Doctor using a tablet with floating medical icons and holographic brain.

How AI is Poised to Rewire the Foundations of Medicine

At Web Summit Vancouver, experts speaking on the panel "A History of the Future of Healthcare" delivered a striking message: medicine is moving faster than ever, but it's not fast enough.

This paradox set the stage for a discussion about the transformation of healthcare via artificial intelligence (AI).

While many industries have been completely revolutionized by technology, the healthcare sector has often lagged, clinging to outdated practices. However, the participants agreed that AI is beginning to change that narrative, offering promising solutions and a glimpse into a future of personalized, efficient and proactive care.

Keep reading...Show less
Radiopharm Theranostics

Radiopharm Theranostics Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

×